1 Webster R G, Bean W J, Gorman O T, et al. Evolution and ecology of influenza A viruses. Microbiol Rev, 1992, 56: 152—179 2 Peiris J S, de J, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev, 2007, 20: 243—2673 Kumar S, Tamura K, Jakobsen I B, et al. MEGA2: Molecular evolutionary genetics analysis software. Bioinformatics, 2001, 17: 1244—
4 Thompson J D, Higgins D G, Gibson T J. Clustal W: Improving the sensitivity of progressive multiple sequence alignment through
sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res, 1994, 22: 4673—
5 Schwede T, Kopp J, Guex N, et al. SWISS MODEL: An automated protein homology-modeling server. Nucleic Acids Res, 2003, 31:
6 William H, Andrew D, Klaus S. VMD: Visual molecular dynamics. J Mol Grap, 1996, 14: 33—387 Gabriel G, Herwig A, Klenk H D. Interaction of polymerase subunit PB2 and NP with importin alpha1 is a determinant of host range
of influenza A virus. PLoS Pathog, 2008, 4
8 Qi X, Li X, Rider P, et al. Molecular characterization of highly pathogenic H5N1 avian influenza A viruses isolated from raccoon dogs
9 Obenauer J C, Denson J, Mehta P K, et al. Large-scale sequence analysis of avian influenza isolates. Science, 2006, 311: 1576—
10 Jackson D, Hossain M J, Hickman D, et al. A new influenza virus virulence determinant: The NS1 protein four C-terminal residues
modulate pathogenicity. Proc Natl Acad Sci USA, 2008, 105: 4381—4386
11 Atsushi O, Takashi M, Hideo T. Protonation of histidine and histidine-tryptophan interaction in the activation of the M2 ion channel
from influenza A virus. Biochemistry, 2001, 40: 6053—6060
12 Suzuki H, Saito R, Masuda H, et al. Emergence of amantadine-resistant influenza A viruses: Epidemiological study. J Infect Chemother,
13 Scholtissek C, Quack G, Klenk H D, et al. How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral
14 Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A(H1N1) virus in
15 Parrish C R, Kawaoka Y. The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A
viruses. Annu Rev Microbiol, 2005, 59: 553—586
16 Skehel J J, Wiley D C. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem, 2000,
17 Weis W, Brown J H, Cusack S, et al. Structure of the influenza virus hemagglutinin complexed with its receptor, sialic acid. Nature,
18 Rogers G N, Paulson J C, Daniels R S, et al. Single amino acid substitutions in influenza hemagglutinin change receptor binding speci-
19 Monto A S. The role of antivirals in the control of influenza. Vaccine, 2003, 21: 1796—180020 Hay A J, Wolstenholm A J, Skehel J J, et al. The molecular basis of the specific anti-influenza action of amantadine. EMBO J, 1985, 4:
21 Pinto L H, Holsinger L J, Lamb L A. Influenza virus M2 protein has ion channel activity. Cell, 1992, 69: 517—528 22 Madren L K, Shipman C, Hayden F G. In vitro inhibitory effects of combinations of anti-influenza agents. Antivir Chem Chemother,
23 Varghese J H, McKimm-Breschkin J L, Caldwel J B, et al. The structure of the complex between influenza virus neuraminidase and
sialic acid, the viral receptor. Proteins, 1992, 14: 327—
24 Von Itzstein M, Wu W Y, Kok G K, et al. Rational design of potent sialidase based inhibitors of influenza virus protection. Nature,
25 Hayden F G. Amantadine and rimantadine—clinical aspects. In: Richman D D, ed. Antiviral Drug Resistance. New York: Wiley, 1996.
26 Ziegler T, Hemphill M L, Ziegler M L, et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis,
27 Bright R A, Medina M, Xu X, et al. Incidence of adamantine resistance among influenza A (H3N2) viruses isolated worldwide from
1994 to 2005: A cause for concern. Lancet, 2005, 366: 1175—
28 Ilyushina N A, Govorkova E A, Webster R G. Detection of amantadine-resistant variants among avian influenza viruses isolated in
North America and Asia. Virology, 2005, 341: 102—106
29 Monto A S, Fleming D M, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A
and B virus infections. J Infect Dis, 1999, 180: 254—
30 Lew W, Chen X, Kim C U. Discovery and development of GS4104 (oseltamivir): An orally active influenza neuraminidase inhibitor.
31 McKimm-Breschkin J L. Resistance of influenza viruses to neraminidase inhibitors —A review. Antivir Res, 2000, 47: 1—1732 McKimm-Breschkin J L. Management of influenza virus infections with neuraminidase inhibitors: Detection, incidence, and
implications of drug resistance. Treat Respir Med, 2005, 4: 107—116
33 Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet,
34 Gubareva L V, Matrosovich M N, Brenner M K, et al. Evidence for zanamivir resistance in an immunocompromised child infected with
influenza B virus. J Infect Dis, 1998, 178: 1257—1262
35 Robert M K, Wei M Y, Diana L N, et al. Intracel ular warfare between human influenza viruses and human cells: The roles of the viral
36 Stacey S C, Naomi D S, Gabriele N, et al. Influenza virus NS1 protein induces apoptosis in cultured cells. J Virol, 2001, 75: 7875 37 Adolfo G S, Andrej E, Demetrius M, et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology,
38 Sang H S, Erich H, Robert G W. The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus
39 Gary K G, Mirella S, Terrence M T, et al. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: The role of
the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci USA, 2002, 99: 10736—
40 Aleksandr S L, Samita A, Richard J W, et al. Pathogenesis of Hong Kong H5N1 influenza virus NS gene reassortants in mice: The role
of cytokines and B- and T-cell responses. J Gen Virol, 2005, 86: 1121—
41 Morgan S, Carlo S. PDZ domains and the organization of supramolecular complexes. Annu Rev Neurosci, 2001, 24: 1—29
BENNY NISBET(PPA): “WATERTOREN SAN NICOLAS LO A WORDE FINANCIA CU FONDO HULANDES NATIONAAL RESTAURATIE FONDS !!” SI , CIERTO MINISTRO A CREA IMPRESSION DEN PUEBLO DI ARUBA CU TA FONDO COMPLETO DI PRESUPUESTO DI ARUBA Y CU TA DECISION DI NAN….ESAKI SEGUN PPA NO TA CUADRA CU BERDAD….MAS TANTO DEPARTAMENTO MANERA DOW Y ALGUN OTRO TIN E TAREA DI CONTROLA E RENOVACION. Mirando cu siman
Alfred Nobel Swedish inventor and philanthropist Nobel invented dynamite and blasting caps and held impending financial disaster in 1858, Nobel, because of patents for more than 350 inventions, but he is his fluency in English, was sent to England to try to ne- remembered mostly for the provision he made in his gotiate financing for the business. He failed in this at- last will for the d